Trial Profile
A phase I trial of PSA-activated PSA-PAH1 [PRX 302; PORxin; Protox Therapeutics] therapy for locally recurrent prostate cancer without metastases after primary radiation therapy.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Topsalysin (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 03 Nov 2009 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.
- 13 Feb 2008 Results will be presented on 14 February at the American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium, held in San Francisco, California, USA.
- 02 Nov 2007 Final results have been reported.